Pharmaceutical Technology

DECEMBER 25, 2023

Disitamab vedotin is under clinical development by RemeGen and currently in Phase I for Cervical Cancer.

52

52

Pharmaceutical Technology

DECEMBER 6, 2023

XmAb-662 is under clinical development by Xencor and currently in Phase I for Cervical Cancer.

52

52

Pharmacy Times

JANUARY 9, 2024

The accepted sBLA comes after phase 3 clinical trial results which demonstrated better overall survival, progression-free survival, and confirmed overall response rate than chemotherapy in patients with cervical cancer.

Chemotherapy 48

Chemotherapy 48

Pharmaceutical Technology

JANUARY 4, 2024

XTX-101 is under clinical development by Xilio Therapeutics and currently in Phase II for Cervical Cancer.

40

40

Pharmaceutical Technology

DECEMBER 20, 2023

VTP-200 is under clinical development by Barinthus Biotherapeutics and currently in Phase II for Cervical Cancer.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

Tusamitamab ravtansine is under clinical development by Sanofi and currently in Phase II for Cervical Cancer.

40

40

pharmaphorum

FEBRUARY 9, 2022

In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. One area that is gathering increasing levels of interest is the development of cancer vaccines. A broad front. Prior success.

Vaccines 133

Vaccines Immunity Immunization Compounding 133

Pharmaceutical Technology

NOVEMBER 5, 2023

XB-002 is under clinical development by Exelixis and currently in Phase II for Cervical Cancer.

40

40

Express Pharma

AUGUST 31, 2023

BioNTech’s diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials, predominantly targeting solid tumors such as melanoma, prostate cancer, cervical cancer, non-small cell lung cancer, and pancreatic cancer. per cent of the total mRNA therapy market by 2029.

Immunity 104

Immunity Immunization Vaccines 104

Pharmaceutical Technology

JULY 7, 2023

Oncolytic Virus for Human Papillomavirus Associated Cancer, Human Papillomavirus Infections and Coronavirus Disease 2019 (COVID-19) is under clinical development by Blue Sky Immunotherapies and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN).

40

40

Pharmaceutical Technology

JULY 7, 2023

Oncolytic Virus for Human Papillomavirus Associated Cancer, Human Papillomavirus Infections and Coronavirus Disease 2019 (COVID-19) is under clinical development by Blue Sky Immunotherapies and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN).

40

40

Pharmaceutical Technology

MARCH 1, 2023

MP-0310 is under clinical development by Molecular Partners and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I drugs for Cervical Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. It is developed based on DARPin technology.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Drug Development Diabetes 40

pharmaphorum

OCTOBER 14, 2021

The FDA has approved Merck’s Keytruda as a first-line therapy for advanced cervical cancer. Keytruda (pembrolizumab) can be used in combination with chemotherapy, with or without bevacizumab, to treat patients with persistent, recurrent or metastatic cervical cancer where the tumour expresses a certain level of PD-L1.

Chemotherapy 44

Chemotherapy Research Laboratories Immunity Immunization 44

pharmaphorum

JUNE 27, 2022

Almost half (48%) of cancer clinical trials in the US have no Hispanic or Latin American subjects, and 42% have no black patients, according to a diversity analysis focusing on thousands of studies conducted in the past 15 years. Figure 1: Ethnic composition of cancer clinical trial cohorts in the USA.

109

109

Pharmaceutical Technology

FEBRUARY 23, 2023

Buparlisib hydrochloride is under clinical development by Adlai Nortye Biopharma and currently in Phase II for Mantle Cell Lymphoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Drug Development 52

Drug Development 52

Pharmaceutical Technology

FEBRUARY 19, 2023

Danburstotug is under clinical development by Sorrento Therapeutics and currently in Phase III for Cervical Cancer. According to GlobalData, Phase III drugs for Cervical Cancer have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration.

Drug Development 40

Drug Development 40

European Pharmaceutical Review

JULY 27, 2023

ENHERTU ® (trastuzumab deruxtecan) has demonstrated clinically meaningful progression-free survival (PFS) and overall survival (OS) in topline results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial. These cancers include biliary tract, bladder, cervical, endometrial, ovarian and pancreatic.

88

88

Pharmaceutical Technology

MARCH 23, 2023

Adcetris is currently active in multiple clinical trials, including the ECHELON-3 Phase lll study for patients with relapsed or refractory diffuse large B-cell lymphoma. It is indicated for adults with metastatic cervical cancer as a second-line therapeutic.

Chemotherapy 59

Chemotherapy Compounding 59

PharmaShots

JUNE 15, 2023

In Nov 2021, the clinical results showed that TIL cell therapy + pembrolizumab in immune-checkpoint inhibitor naïve patients showed ORR (57%) in Cervical Cancer, 60% in Melanoma with 30% CR & 39% in Head & Neck Cancer The Iovance TIL platform showed promising clinical data across multiple solid tumors.

Immunity 40

Immunity Immunization 40

PharmaShots

JUNE 2, 2023

Impact Therapeutics Entered into a License and Collaboration Agreement with Eikon Therapeutics to Develop and Commercialize IMP1734 Date: June 02, 2023 | Tags: Impact Therapeutics, Eikon Therapeutics, IMP1734, Pharma, China, Hong Kong, Macau, Taiwan BMS’ Mavacamten Receives the NICE Recommendation for the Treatment of Obstructive Hypertrophic (..)

Biosimilars 40

Biosimilars 40

Pharmafile

MARCH 21, 2023

read more

Immunity 52

Immunity Immunization 52

pharmaphorum

AUGUST 22, 2021

The move comes amid reports that some people are being offered RAS for the prevention or treatment of breast cancer, sometimes as part of a clinical trial, even though many of the studies are being undertaken “without the FDA oversight required.”

93

93

Pharmaceutical Technology

MAY 31, 2023

ATRN-119 is under clinical development by Aprea Therapeutics and currently in Phase II for Solid Tumor. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It also has pre-clinical research and development to extend its product development.

Drug Development 40

Drug Development 40

Pharmaceutical Technology

JUNE 10, 2023

TAS-117 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Chondrosarcoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It was under development for the treatment of gastric cancer and multiple myeloma.

Drug Development 40

Drug Development 40

Pharmaceutical Technology

JUNE 10, 2023

TAS-117 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Chondrosarcoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It was under development for the treatment of gastric cancer and multiple myeloma.

Drug Development 40

Drug Development 40

pharmaphorum

MARCH 30, 2022

Roche has suffered a setback with its much-anticipated pairing of anti-TIGIT antibody tiragolumab and PD-L1 inhibitor Tecentriq in small cell lung cancer (SCLC), in a blow to its ambitions in combination cancer immunotherapy. The post Roche hit by failure of TIGIT drug tiragolumab in lung cancer appeared first on.

Chemotherapy 97

Chemotherapy Immunity Immunization 97

Pharmaceutical Technology

MARCH 1, 2023

MP-0310 is under clinical development by Molecular Partners and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. The drug candidate is administered through intravenous route.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Drug Development Diabetes 40

Pharmaceutical Technology

AUGUST 19, 2022

The European Commission (EC) has granted approval for Celltrion Healthcare ’s Vegzelma (CT-P16) to treat metastatic breast cancer, advanced and/or metastatic renal cell cancer, non-small cell lung cancer, ovarian cancer, metastatic carcinoma of the colon or rectum and cervical cancer.

Biosimilars 52

Biosimilars 52

Pharmaceutical Technology

FEBRUARY 20, 2023

ABN-401 is under clinical development by Abion and currently in Phase II for Solid Tumor. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The drug candidate is a triazolopyrazine derivative. Abion is headquartered in Seoul City, Seoul, South Korea.

Drug Development 40

Drug Development 40

pharmaphorum

MARCH 22, 2021

million grant from the European Commission to accelerate clinical development of mRNA therapies for hard-to-treat cancers. But it was cancer that the German biotech originally targeted with the technology, which is capable of converting cells into “drug factories” to fight a range of diseases.

Vaccines 75

Vaccines 75

Pharmaceutical Technology

FEBRUARY 26, 2023

Cellular Immunotherapy for Non-Small Cell Lung Cancer is under clinical development by Iovance Biotherapeutics and currently in Phase II for Non-Small Cell Lung Cancer. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Buy the report here.

Immunity 40

Immunity Immunization Drug Development 40

Pharmaceutical Technology

MAY 31, 2023

Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Vaccines Drug Development 40

Pharmaceutical Technology

FEBRUARY 19, 2023

Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Solid Tumor. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Chemotherapy 40

Chemotherapy Diabetes Drug Development 40

pharmaphorum

DECEMBER 6, 2022

It’s been a torrid few years for Summit, which has seen two lead drug candidates – ezutromid for Duchenne muscular dystrophy and Clostridium difficile infection therapy ridinilazole –fail in mid- to late-stage clinical trials.

Chemotherapy 52

Chemotherapy Immunity Immunization 52

PharmaShots

APRIL 21, 2023

Oblato Reports the First Patient Enrolment of OKN-007 in the P-I Clinical Trial for Recurrent High-Grade Glioma Date: Apr 21, 2023 | Tags: Oblato, OKN-007, Recurrent High-Grade Glioma, Regulatory, Henry Ford Health System CARsgen's CT041 Receives the US FDA’s IND Clearance for the Postoperative Adjuvant Therapy of Pancreatic Cancer Date: (..)

Labelling 40

Labelling 40

Pharmaceutical Technology

JUNE 6, 2023

According to Globaldata, it is involved in 1 clinical trial, which is ongoing. The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. Buy the model here. It is developed based on ZymeLink technology. It is administered through intravenous route.

40

40

Pharmaceutical Technology

JUNE 6, 2023

Ecubectedin is a small molecule commercialized by Pharma Mar, with a leading Phase II program in Hormone Sensitive Breast Cancer. According to Globaldata, it is involved in 5 clinical trials, which are ongoing. Pharma Mar Overview Pharma Mar discovers, develops and markets marine-derived drugs to treat cancer.

Compounding 40

Compounding 40